▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Oncternal Therapeutics (NASDAQ: ONCT)

Some price data may be temporarily unavailable.

Oncternal Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
ONCT	-92.30%	-99.50%	-65.32%	-100%
S&P	+10.93%	+85.96%	+13.20%	+106%

Oncternal Therapeutics Company Info

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

News & Analysis

Featured Article

Why Oncternal Therapeutics Stock Is Popping Today

This analyst is excited about the company's prospects.

Prosper Junior Bakiny | Apr 7, 2021

Valuation

Earnings Transcripts

Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Transcript

ONCT earnings call for the period ending June 30, 2022.

Motley Fool Transcribing | Aug 10, 2022

Oncternal Therapeutics, Inc. (ONCT) Q1 2022 Earnings Call Transcript

ONCT earnings call for the period ending March 31, 2022.

Motley Fool Transcribing | May 6, 2022

Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Call Transcript

ONCT earnings call for the period ending December 31, 2021.

Motley Fool Transcribing | Mar 10, 2022

Oncternal Therapeutics, Inc. (ONCT) Q3 2021 Earnings Call Transcript

ONCT earnings call for the period ending September 30, 2021.

Motley Fool Transcribing | Nov 5, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services